Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

7(77.8%)

Phase 2

2(22.2%)

9Total

Phase 1(7)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT02643056Phase 2Completed

Study to Investigate the Efficacy of Panitumumab in Platinum-resistant Advanced Head and Neck Squamous Cancer

Role: lead

NCT01748019Phase 1Completed

ST1968 Intravenous (Weekly) in Solid Tumors

Role: collaborator

NCT01148628Phase 1Unknown

Dose-finding Study of CAELYXTM and RAD001 in Patients With Advanced Solid Tumors

Role: lead

NCT01159418Phase 1Unknown

LBH589 Oral in Combination With Carboplatin and Paclitaxel in Advanced Solid Tumors

Role: lead

NCT01221103Phase 1Unknown

Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL)

Role: lead

NCT01155505Phase 1Unknown

Lenalidomide and Paclitaxel in Advanced Solid Tumors

Role: lead

NCT01226056Phase 1Suspended

Sorafenib in Combination With RAD001 in Advanced Solid Tumors Selected on Molecular Targets

Role: lead

NCT01222936Phase 2Completed

LBH Phase II in Small Cell Lung Cancer (SCLC)

Role: lead

NCT01220284Phase 1Unknown

Satraplatin and Vinorelbine in Advanced Solid Tumors

Role: lead

All 9 trials loaded